Sign Up to like & get recommendations! 2
Published in 2023 at "Journal of surgical oncology"
DOI: 10.1002/jso.27242
Abstract: BACKGROUND AND OBJECTIVES In patients with colon cancer with synchronous liver metastasis, treatment algorithms are complex and often require multidisciplinary evaluation. Neoadjuvant therapy is frequently utilized, but there is an unclear relationship with postoperative outcomes… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Abdominal Radiology"
DOI: 10.1007/s00261-018-1867-7
Abstract: PurposeTo explore the value of gadolinium-enhanced MRI combined with diffusion-weighted MRI (Gd-enhanced MRI with DWI) in addition to contrast-enhanced CT (CECT) for detection of synchronous liver metastases for potentially resectable pancreatic cancer.MethodsBy means of a… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Updates in Surgery"
DOI: 10.1007/s13304-021-01100-9
Abstract: At the time of diagnosis synchronous colorectal cancer, liver metastases (SCRLM) account for 15–25% of patients. If primary tumour and synchronous liver metastases are resectable, good results may be achieved performing surgical treatment incorporated into… read more here.
Sign Up to like & get recommendations! 1
Published in 2017 at "Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique"
DOI: 10.1016/j.canrad.2017.07.021
Abstract: The prognosis of patients with rectal cancer and synchronous liver metastasis has improved thanks to chemotherapy and rectal and liver surgery progresses. However, there is no consensus about optimal management and practices remain heterogeneous. A… read more here.
Sign Up to like & get recommendations! 1
Published in 2019 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2019.05.004
Abstract: Around one fifth of patients with rectal cancer (RC) have synchronous metastatic disease at the diagnosis. The optimal treatment sequence for patients with RC and synchronous liver metastases (LM) is complex and unclear, missing strong,… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Scientific Reports"
DOI: 10.1038/s41598-018-24539-0
Abstract: Most pancreatic cancer (PC) patients manifest multiple liver metastases at the time of diagnosis. Activated platelets play a key role in tumor growth and tumor metastases. Mean platelet volume (MPV) is a platelet index and… read more here.
Sign Up to like & get recommendations! 0
Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000029533
Abstract: Abstract Background: The treatment of gastric cancer (GC) with synchronous liver metastasis is still controversial. This systematic review and network meta-analysis was designed to evaluate the long-term outcomes after different treatments of GC with synchronous… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Annals of surgery"
DOI: 10.1097/sla.0000000000005753
Abstract: OBJECTIVE To evaluate long-term oncologic outcomes of patients with stage IV pancreatic ductal adenocarcinoma (PDAC) and identify survival benchmarks for comparison when considering resection in these patients. SUMMARY BACKGROUND DATA Highly selected cohorts of patients… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Gastroenterology Research and Practice"
DOI: 10.1155/2019/6397513
Abstract: Aims Liver metastases occur in approximately 25% of colorectal cancer (CRC) patients and cause more than 90% of deaths in CRC. Platelets play a crucial role in cancer progression and metastases. We aimed to investigate… read more here.
Sign Up to like & get recommendations! 1
Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e15567
Abstract: e15567Background: Synchronous Liver Metastases occur in approximately 20% of patients with Rectal Cancer. Patients with SCRLM are a heterogeneous group. Potential cure is dependent on the ability t... read more here.
Sign Up to like & get recommendations! 1
Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.4049
Abstract: 4049Background: Per SEER database, approximately 21% of patients have synchronous metastatic disease at presentation with a median 5 year survival of 14%. Liver is by far the most common site of me... read more here.